Skip to main content
TipRanks
Go Ultimate75% OFF

Ypsomed Holding AG (0QLQ) Share Price & Analysis

3 Followers

0QLQ Stock Chart & Stats

CHF 421.80-CHF 7.60(-1.77%)
At close: 4:30 PM GMT
CHF350CHF375CHF400CHF425Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
CHF 421.80 - CHF 428.00
52-Week Range
CHF 263.50 - CHF 437.20
Previous Close
CHF 429.40
Volume
N/A
Average Volume (3M)
881
Market Cap
CHF 5.54B
Enterprise Value
CHF 5.12B
Total Cash (Recent Filing)
CHF 37.17M
Total Debt (Recent Filing)
CHF 337.31M
Price to Earnings (P/E)
33.4
Beta
0.87
Next Earnings
May 26, 2027 (Est.)
Dividend Yield
1.04%

Bulls Say, Bears Say

Bulls Say

Autoinjector-led Market Position And Growth

Ypsomed’s strong autoinjector position supports durable growth because its platforms are embedded in a broad range of pharmaceutical programs. The combination of high current exposure, customer adoption and recurring commercialization opportunities should reinforce competitive relevance over the next several quarters.

Expanding Customer And Product Pipeline

A broad, expanding pipeline diversifies future revenue beyond individual products or customers and creates multiple paths to commercialization. New projects, therapeutic applications and customer wins can translate into longer-term device supply opportunities as programs advance through clinical and commercial stages.

Strong Profitability And Operating Cash Generation

Material improvement in earnings and operating cash generation demonstrates stronger underlying economics and gives Ypsomed greater capacity to fund expansion. High profitability can support continued innovation, capacity investment and balance-sheet resilience while the business scales its delivery-system platforms.

Bears Say

Persistent Negative Free Cash Flow

Sustained negative free cash flow means strong operating earnings are not yet converting fully into discretionary cash. Continued investment or working-capital demands could constrain internal funding, increase reliance on financing and reduce flexibility if growth projects take longer to mature.

Heavy Capacity Investment Cycle

The elevated investment program creates execution and returns risk over the next two to six months, as new capacity must ramp efficiently to absorb its cost. Until spending declines and facilities contribute meaningfully, cash conversion and near-term financial flexibility are likely to remain pressured.

Near-term Margin Pressure And Contract Phase-outs

Capacity ramp costs, volume-based pricing and the loss of Sanofi manufacturing revenue may weigh on profitability even as sales grow. These factors can dilute mix and margins during the transition, requiring successful execution and new volume wins to preserve the company’s earnings trajectory.

Ypsomed Holding AG News

0QLQ FAQ

What was Ypsomed Holding AG’s price range in the past 12 months?
Ypsomed Holding AG lowest share price was CHF263.50 and its highest was CHF437.20 in the past 12 months.
What is Ypsomed Holding AG’s market cap?
Ypsomed Holding AG’s market cap is CHF5.54B.
When is Ypsomed Holding AG’s upcoming earnings report date?
Ypsomed Holding AG’s next earnings report is estimated for May 26, 2027 (not yet confirmed), which is in 188 days.
How were Ypsomed Holding AG’s earnings last quarter?
Ypsomed Holding AG released its earnings results on Nov 11, 2026. The company reported CHF6.5 earnings per share for the quarter, beating the consensus estimate of CHF5.227 by CHF1.273.
Is Ypsomed Holding AG overvalued?
According to Wall Street analysts Ypsomed Holding AG’s price is currently Undervalued.
Does Ypsomed Holding AG pay dividends?
Ypsomed Holding AG pays an annual dividend of CHF4.4 which represents an annual dividend yield of 1.04%. See more information on Ypsomed Holding AG dividends here
What is Ypsomed Holding AG’s EPS estimate?
Ypsomed Holding AG’s EPS estimate is 8.64.
How many shares outstanding does Ypsomed Holding AG have?
Ypsomed Holding AG has 13,149,739 shares outstanding.
What happened to Ypsomed Holding AG’s price movement after its last earnings report?
Ypsomed Holding AG reported an EPS of CHF6.5 in its last earnings report, beating expectations of CHF5.227. Following the earnings report the stock price went up 4.093%.
Which hedge fund is a major shareholder of Ypsomed Holding AG?
Currently, no hedge funds are holding shares in GB:0QLQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology